報價延遲最少15分鐘:2024/05/09 16:00 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
54.34 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.13/0.08
|
|
企業價值
13.41B
|
| 資產負債 |
|
每股賬面淨值
17.11
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
2.50B
|
|
每股收益
13.09
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/09 16:00 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy forbreast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too. |